|This company is or has gone private. Information about the company may be limited and outdated.|
SGX Pharmaceuticals Inc., formerly known as Structural GenomiX, Inc., is a biotechnology company focused on the discovery, development and commercialization of cancer therapeutics. The company had licensed exclusive worldwide rights to Troxatyl from Shire BioChem Inc. in July 2004. It was the company's only late stage drug candidate which went through a pivotal phase II/III clinical trial for the third-line treatment of acute myelogenous leukemia (AML), but the company announced its discontinuation on August 28, 2006 due to efficacy insufficiency.
After the failure of its Troxatyl franchise, the company has shifted its focus on its proprietary FAST technology to develop novel drug candidates for cancer and other disease. FAST technology is based upon the use of small fragments of drug-like molecules, known as Fragments of Active Structures (FAST). The company has successfully applied FAST to generate selective small molecule compounds for many proteins (drug targets) that have been implicated in cancers and other diseases. SGX has co-operation with Novartis, Eli Lilly, Cystic Foundation, Roche, Amgen, Biogen Idec, OSI Pharma, NIH and Serono for development of new drug candidates using its FAST technology. However, all these programs are in early discovery stage of development.
SGX Pharma is headquartered in San Diego, California and employs roughly 118 full-time employees. The company was incorporated in Delaware on July 16, 1998 and went public in February 2006.